Spire Healthcare Group (LON:SPI – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Deutsche Bank Aktiengesellschaft in a research note issued on Friday,London Stock Exchange reports. They presently have a GBX 245 price target on the stock. Deutsche Bank Aktiengesellschaft’s price target would indicate a potential upside of 8.11% from the stock’s current price.
Spire Healthcare Group Price Performance
LON SPI traded up GBX 2.13 during trading on Friday, reaching GBX 226.63. The company’s stock had a trading volume of 57,164,754 shares, compared to its average volume of 4,277,108. The stock has a market capitalization of £907.86 million, a PE ratio of 56.66, a P/E/G ratio of 1.06 and a beta of 0.91. The company has a debt-to-equity ratio of 177.14, a current ratio of 0.63 and a quick ratio of 0.74. The firm has a fifty day moving average of GBX 163.68 and a 200 day moving average of GBX 185.52. Spire Healthcare Group has a one year low of GBX 140.80 and a one year high of GBX 256.50.
Spire Healthcare Group (LON:SPI – Get Free Report) last released its quarterly earnings results on Friday, March 6th. The company reported GBX 9.60 earnings per share for the quarter. Spire Healthcare Group had a return on equity of 2.22% and a net margin of 1.04%. Analysts expect that Spire Healthcare Group will post 15.6634747 EPS for the current fiscal year.
Key Stories Impacting Spire Healthcare Group
- Positive Sentiment: Toscafund has reportedly made a £1 billion takeover proposal for Spire Healthcare, sending the shares sharply higher as investors price in a potential buyout premium. Spire Healthcare shares surge 38% on £1bn takeover proposal from Toscafund
- Positive Sentiment: Spire said it would support a £1 billion bid from Toscafund, reinforcing market expectations that a deal could move forward. Spire Healthcare says would back GBP1 billion bid from Toscafund
- Positive Sentiment: Reuters reported that Toscafund is proposing a $1.35 billion buyout of London-listed Spire Healthcare, adding further credibility to the takeover story. London’s Spire Healthcare gets $1.35 billion buyout proposal from Toscafund
- Positive Sentiment: Spire also confirmed full-year outlook and said private revenue is growing strongly, while maintaining 2026 earnings guidance after stable early-year trading. Spire Healthcare confirms full-year outlook as private revenue grows strongly
- Neutral Sentiment: Shareholders approved all resolutions at Spire’s 2026 AGM, which signals governance support but is less likely to be the main stock-moving driver. Spire Healthcare Wins Strong Shareholder Backing at 2026 AGM
About Spire Healthcare Group
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments.
See Also
- Five stocks we like better than Spire Healthcare Group
- 3 AI Data Center Stocks Worth Watching for Capital Rotation
- McDonald’s Is the Cheapest It’s Been in Years—Does That Make It a Buy?
- Karman: Defense Darling’s Outlook Strengthens After 40% Drop
- Aeluma’s Post-Earnings Dip Creates a Buying Opportunity
Receive News & Ratings for Spire Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spire Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.
